Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Frequency Therapeutics, Inc is a biotechnology business based in the US. Frequency Therapeutics shares (FREQ) are listed on the NASDAQ and all prices are listed in US Dollars. Frequency Therapeutics employs 43 staff and has a trailing 12-month revenue of around USD$44.7 million.
Since the stock market crash in March caused by coronavirus, Frequency Therapeutics's share price has had significant negative movement.
Its last market close was USD$23.45, which is 4.64% down on its pre-crash value of USD$24.59 and 50.88% up on the lowest point reached during the March crash when the shares fell as low as USD$15.5425.
If you had bought USD$1,000 worth of Frequency Therapeutics shares at the start of February 2020, those shares would have been worth USD$665.96 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$880.31.
|Latest market close||USD$23.45|
|52-week range||USD$13.6 - USD$28.78|
|50-day moving average||USD$20.6806|
|200-day moving average||USD$19.9057|
|Wall St. target price||USD$35|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.6355|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||-13.98%|
|1 month (2020-10-30)||7.18%|
|3 months (2020-08-28)||19.34%|
|6 months (2020-05-29)||26.35%|
|1 year (2019-11-29)||40.42%|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$44.7 million|
|Gross profit TTM||USD$12.9 million|
|Return on assets TTM||-10.22%|
|Return on equity TTM||-17.75%|
|Market capitalisation||USD$743.2 million|
TTM: trailing 12 months
There are currently 4.2 million Frequency Therapeutics shares held short by investors – that's known as Frequency Therapeutics's "short interest". This figure is 2.2% up from 4.1 million last month.
There are a few different ways that this level of interest in shorting Frequency Therapeutics shares can be evaluated.
Frequency Therapeutics's "short interest ratio" (SIR) is the quantity of Frequency Therapeutics shares currently shorted divided by the average quantity of Frequency Therapeutics shares traded daily (recently around 222119.11298838). Frequency Therapeutics's SIR currently stands at 18.94. In other words for every 100,000 Frequency Therapeutics shares traded daily on the market, roughly 18940 shares are currently held short.
However Frequency Therapeutics's short interest can also be evaluated against the total number of Frequency Therapeutics shares, or, against the total number of tradable Frequency Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Frequency Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Frequency Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.1377% of the tradable shares (for every 100,000 tradable Frequency Therapeutics shares, roughly 138 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Frequency Therapeutics.
Find out more about how you can short Frequency Therapeutics stock.
We're not expecting Frequency Therapeutics to pay a dividend over the next 12 months.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.